Knowledge Ecology International
Attending and mending the knowledge ecosystem
Menu Close
  • About
  • Areas of work
  • Coronavirus
  • Xtandi
  • Listserves
  • Videos
  • Publications
  • Databases
  • Donate
Home»Blogs»The cost of trials used to support the initial FDA approval of risdiplam (Evrysdi)

The cost of trials used to support the initial FDA approval of risdiplam (Evrysdi)

Posted on April 23, 2025 by James Love

Cost of initial risdiplam trials

The cost of trials used to support the initial FDA approval of risdiplam (Evrysdi)
KEI Research Note 2025:2
James Packard Love

April 23, 2025

Access to Medicine, Economics, Orphan Drugs, Research and Development evrysdi, risdiplam, Roche

Post navigation

WHO Pandemic agreement text as of Wednesday, 16 April 2025 at 1:57 CEST

Categories

  • About
  • Access to Knowledge
  • Access to Medicine
  • AI
  • Competition
  • Delinkage
  • Economics
  • Events
  • Evidence
  • Government Funded research
  • influence
  • Intellectual Property Rights
  • Legislation
  • Litigation
  • Lobbying
  • Marketing
  • Meetings
  • Negotiations
  • Nuclear Proliferation
  • Orphan Drugs
  • Presentations
  • Privacy
  • Public Goods
  • Research and Development
  • Site Articles
  • Timelines
  • Trade
  • Transparency
  • WHO
  • WIPO
  • WTO
© 2025 Knowledge Ecology International. All rights reserved.
Hiero by aThemes